PIK3CA H1047R
|
CRC
|
PIK3CA H1047R
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PIK3CA H1047R
|
HER2 Positive Breast Cancer
|
PIK3CA H1047R
|
HER2 Positive Breast Cancer
|
PF-05212384 + Herzuma (trastuzumab biosimilar) Sensitive: C3 – Early Trials
|
PF-05212384 + Herzuma (trastuzumab biosimilar) Sensitive: C3 – Early Trials
|
PIK3CA H1047R
|
NSCLC
|
PIK3CA H1047R
|
NSCLC
|
trametinib + dabrafenib Sensitive: C3 – Early Trials
|
trametinib + dabrafenib Sensitive: C3 – Early Trials
|
PIK3CA H1047R
|
Breast Cancer
|
PIK3CA H1047R
|
Breast Cancer
|
TAS-117 Sensitive: C3 – Early Trials
|
TAS-117 Sensitive: C3 – Early Trials
|
PIK3CA H1047R
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA H1047R
|
Hormone Receptor Positive Breast Cancer
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
PIK3CA H1047R
|
Melanoma
|
PIK3CA H1047R
|
Melanoma
|
dabrafenib Sensitive: C4 – Case Studies
|
dabrafenib Sensitive: C4 – Case Studies
|
PIK3CA H1047R
|
HER2 Positive Breast Cancer
|
PIK3CA H1047R
|
HER2 Positive Breast Cancer
|
everolimus Sensitive: C4 – Case Studies
|
everolimus Sensitive: C4 – Case Studies
|
PIK3CA H1047R
|
Thyroid Gland Anaplastic Carcinoma
|
PIK3CA H1047R
|
Thyroid Gland Anaplastic Carcinoma
|
trametinib + dabrafenib + everolimus Sensitive: C4 – Case Studies
|
trametinib + dabrafenib + everolimus Sensitive: C4 – Case Studies
|
PIK3CA H1047R
|
Salivary Gland Cancer
|
PIK3CA H1047R
|
Salivary Gland Cancer
|
vandetanib Sensitive: C4 – Case Studies
|
vandetanib Sensitive: C4 – Case Studies
|
PIK3CA H1047R
|
Colon Cancer
|
PIK3CA H1047R
|
Colon Cancer
|
PF-05212384 Sensitive: D – Preclinical
|
PF-05212384 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
SCCHN
|
PIK3CA H1047R
|
SCCHN
|
trametinib Sensitive: D – Preclinical
|
trametinib Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Endometrial Cancer
|
PIK3CA H1047R
|
Endometrial Cancer
|
MEN1611 Sensitive: D – Preclinical
|
MEN1611 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
CRC
|
PIK3CA H1047R
|
CRC
|
MEN1611 Sensitive: D – Preclinical
|
MEN1611 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Breast Cancer
|
PIK3CA H1047R
|
Breast Cancer
|
trastuzumab + lapatinib Resistant: D – Preclinical
|
trastuzumab + lapatinib Resistant: D – Preclinical
|
PIK3CA H1047R
|
Breast Cancer
|
PIK3CA H1047R
|
Breast Cancer
|
trastuzumab + MEN1611 Sensitive: D – Preclinical
|
trastuzumab + MEN1611 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Breast Cancer
|
PIK3CA H1047R
|
Breast Cancer
|
GDC-0941 Sensitive: D – Preclinical
|
GDC-0941 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
HER2 Positive Breast Cancer
|
PIK3CA H1047R
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: D – Preclinical
|
ado-trastuzumab emtansine Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Head and Neck Cancer
|
PIK3CA H1047R
|
Head and Neck Cancer
|
alpelisib Sensitive: D – Preclinical
|
alpelisib Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Ovarian Cancer
|
PIK3CA H1047R
|
Ovarian Cancer
|
MEN1611 Sensitive: D – Preclinical
|
MEN1611 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Ovarian Cancer
|
PIK3CA H1047R
|
Ovarian Cancer
|
LX-086 Sensitive: D – Preclinical
|
LX-086 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Head and Neck Cancer
|
PIK3CA H1047R
|
Head and Neck Cancer
|
SHR-A1307 Sensitive: D – Preclinical
|
SHR-A1307 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Thyroid Gland Anaplastic Carcinoma
|
PIK3CA H1047R
|
Thyroid Gland Anaplastic Carcinoma
|
MK-2206 Sensitive: D – Preclinical
|
MK-2206 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
HER2 Negative Breast Cancer
|
PIK3CA H1047R
|
HER2 Negative Breast Cancer
|
LX-086 Sensitive: D – Preclinical
|
LX-086 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
SCCHN
|
PIK3CA H1047R
|
SCCHN
|
GDC-0941 Resistant: D – Preclinical
|
GDC-0941 Resistant: D – Preclinical
|
PIK3CA H1047R
|
SCCHN
|
PIK3CA H1047R
|
SCCHN
|
BMS-722782 Resistant: D – Preclinical
|
BMS-722782 Resistant: D – Preclinical
|
PIK3CA H1047R
|
SCCHN
|
PIK3CA H1047R
|
SCCHN
|
PF-3845 Resistant: D – Preclinical
|
PF-3845 Resistant: D – Preclinical
|
PIK3CA H1047R
|
SCCHN
|
PIK3CA H1047R
|
SCCHN
|
PF-05212384 Sensitive: D – Preclinical
|
PF-05212384 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
SCCHN
|
PIK3CA H1047R
|
SCCHN
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
PIK3CA H1047R
|
SCCHN
|
PIK3CA H1047R
|
SCCHN
|
RTB101 Sensitive: D – Preclinical
|
RTB101 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Thyroid Gland Carcinoma
|
PIK3CA H1047R
|
Thyroid Gland Carcinoma
|
temsirolimus + BAY86-9766 Sensitive: D – Preclinical
|
temsirolimus + BAY86-9766 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
SCCHN
|
PIK3CA H1047R
|
SCCHN
|
GDC-0032 Sensitive: D – Preclinical
|
GDC-0032 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
SCCHN
|
PIK3CA H1047R
|
SCCHN
|
cetuximab + RTB101 Sensitive: D – Preclinical
|
cetuximab + RTB101 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
HCC
|
PIK3CA H1047R
|
HCC
|
palbociclib + alpelisib Sensitive: D – Preclinical
|
palbociclib + alpelisib Sensitive: D – Preclinical
|
PIK3CA H1047R
|
HCC
|
PIK3CA H1047R
|
HCC
|
alpelisib + CB-228 Sensitive: D – Preclinical
|
alpelisib + CB-228 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
HCC
|
PIK3CA H1047R
|
HCC
|
alpelisib Resistant: D – Preclinical
|
alpelisib Resistant: D – Preclinical
|
PIK3CA H1047R
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA H1047R
|
Hormone Receptor Positive Breast Cancer
|
abemaciclib + RLY-2608 Sensitive: D – Preclinical
|
abemaciclib + RLY-2608 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA H1047R
|
Hormone Receptor Positive Breast Cancer
|
palbociclib + RLY-2608 Sensitive: D – Preclinical
|
palbociclib + RLY-2608 Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Hormone Receptor Positive Breast Cancer
|
PIK3CA H1047R
|
Hormone Receptor Positive Breast Cancer
|
RLY-2608 Resistant: D – Preclinical
|
RLY-2608 Resistant: D – Preclinical
|
PIK3CA H1047R
|
Melanoma
|
PIK3CA H1047R
|
Melanoma
|
trametinib + alpelisib Sensitive: D – Preclinical
|
trametinib + alpelisib Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Melanoma
|
PIK3CA H1047R
|
Melanoma
|
dabrafenib + alpelisib Sensitive: D – Preclinical
|
dabrafenib + alpelisib Sensitive: D – Preclinical
|
PIK3CA H1047R
|
Melanoma
|
PIK3CA H1047R
|
Melanoma
|
trametinib + dabrafenib Resistant: D – Preclinical
|
trametinib + dabrafenib Resistant: D – Preclinical
|
PIK3CA H1047R
|
Melanoma
|
PIK3CA H1047R
|
Melanoma
|
trametinib Resistant: D – Preclinical
|
trametinib Resistant: D – Preclinical
|